John D Mathias

US Patent:

20200377511, Dec 3, 2020

Filed:

Aug 18, 2020

Appl. No.:

16/996117

Inventors:

- New York NY, US
Katherine Lin Lee - West Newton MA, US
Mark Edward Bunnage - Concord MA, US
Seungil Han - Mystic CT, US
David Hepworth - Concord MA, US
Frank Eldridge Lovering - Acton MA, US
John Paul Mathias - Concord MA, US
Nikolaos Papaioannou - Newton MA, US
Betsy Susan Pierce - East Lyme CT, US
Joseph Walter Strohbach - Wentzville MO, US
Stephen Wayne Wright - Old Lyme CT, US
Christoph Wolfgang Zapf - Marlborough MA, US
Lori Krim Gavrin - Villanova PA, US
Arthur Lee - San Carlos CA, US
David Randolph Anderson - Salem CT, US
Kevin Joseph Curran - Somerset NJ, US
Christoph Martin Dehnhardt - Burnaby, CA
Eddine Saiah - Brookline MA, US
Joel Adam Goldberg - New Orleans LA, US
Xiaolun Wang - San Diego CA, US
Horng-Chih Huang - Chesterfield MO, US
Richard Vargas - Bedford MA, US
Michael Dennis Lowe - White Plains NY, US
Akshay Patny - Waltham MA, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 491/056
C07F 7/18
C07D 401/14
C07D 405/14
C07D 217/02
C07D 217/22
C07D 217/24
C07C 69/94
C07D 239/86
C07D 239/88
C07D 263/24
C07D 207/273
C07D 498/04
C07D 209/52
A61K 31/4015
A61K 31/47
A61K 31/4709
A61K 31/4725
A61K 31/517
A61K 31/5377
A61K 31/541
A61K 45/06
C07D 207/26
C07D 215/48
C07D 401/12
C07D 403/12
C07D 405/12
C07D 407/14
C07D 413/12
C07D 417/12
C07D 487/04
A61K 31/40
C07D 207/08
C07D 207/267

Abstract:

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia,as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

US Patent:

20200017512, Jan 16, 2020

Filed:

Sep 20, 2019

Appl. No.:

16/578277

Inventors:

- Bethesda MD, US
David Christopher Limburg - Salem CT, US
John Paul Mathias - Concord MA, US
Atli Thorarensen - Stow MA, US
Rajiah Aldrin Denny - Sharon MA, US
Christoph Wolfgang Zapf - Oakland CA, US
Daniel Elbaum - Newman MA, US
Lori Krim Gavrin - Villanova PA, US
Ivan Viktorovich Efremov - Chestnut MA, US

International Classification:

C07D 487/04
A61P 11/12
A61K 31/519
A61K 45/06

Abstract:

The present invention relates to methods of using compounds of Formula I,

US Patent:

20190330219, Oct 31, 2019

Filed:

Jul 9, 2019

Appl. No.:

16/506883

Inventors:

- Bethesda MD, US
David Christopher Limburg - Salem CT, US
John Paul Mathias - Concord MA, US
Atli Thorarensen - Stow MA, US
John James Mousseau - Norwich CT, US
Rajiah Aldrin Denny - Sharon MA, US
Christoph Wolfgang Zapf - Oakland CA, US
Ivan Viktorovich Efremov - Chestnut MA, US

International Classification:

C07D 487/04
A61P 11/00

Abstract:

The present invention relates to 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

US Patent:

20190292157, Sep 26, 2019

Filed:

Apr 10, 2019

Appl. No.:

16/380256

Inventors:

- New York NY, US
Jeffrey Scott Condon - Melrose MA, US
Andrew Christopher Flick - Kirkland WA, US
Ariamala Gopalsamy - Lexington MA, US
Steven J. Kirincich - Concord MA, US
John Paul Mathias - Concord MA, US
Joseph Walter Strohbach - Wentzville MO, US
Jason Shaoyun Xiang - Winchester MA, US
Li Huang Xing - Lexington MA, US
Xiaolun Wang - San Diego CA, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 239/42
A61P 35/00
A61P 1/04
A61P 1/00
C07D 405/10
A61K 31/505
C07D 401/12
C07D 241/14
C07D 239/28
C07D 403/12

Abstract:

Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure ofas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

US Patent:

20190270751, Sep 5, 2019

Filed:

May 14, 2019

Appl. No.:

16/411679

Inventors:

- New York NY, US
Katherine Lin Lee - West Newton MA, US
Mark Edward Bunnage - Concord MA, US
Seungil Han - Mystic CT, US
David Hepworth - Concord MA, US
Frank Eldridge Lovering - Acton MA, US
John Paul Mathias - Concord MA, US
Nikolaos Papaioannou - Newton MA, US
Betsy Susan Pierce - East Lyme CT, US
Joseph Walter Strohbach - Wentzville MO, US
Stephen Wayne Wright - Old Lyme CT, US
Christoph Wolfgang Zapf - Marlborough MA, US
Lori Krim Gavrin - Villanova PA, US
Arthur Lee - San Carlos CA, US
David Randolph Anderson - Salem CT, US
Kevin Joseph Curran - Somerset NJ, US
Christoph Martin Dehnhardt - Burnaby, CA
Eddine Saiah - Brookline MA, US
Joel Adam Goldberg - New Orleans LA, US
Xiaolun Wang - San Diego CA, US
Horng-Chih Huang - Chesterfield MO, US
Richard Vargas - Bedford MA, US
Michael Dennis Lowe - White Plains NY, US
Akshay Patny - Waltham MA, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 491/056
C07F 7/18
A61K 31/4015
C07D 207/267
C07D 207/08
C07D 209/52
C07D 498/04
C07D 207/273
C07D 263/24
C07D 239/88
C07D 239/86
C07C 69/94
C07D 217/24
C07D 217/22
C07D 217/02
C07D 405/14
C07D 401/14
C07D 487/04
A61K 31/47
A61K 31/4709
A61K 31/4725
A61K 31/517
A61K 31/5377
A61K 31/541
A61K 45/06
C07D 207/26
C07D 215/48
C07D 401/12
C07D 403/12
C07D 405/12
C07D 407/14
C07D 413/12
C07D 417/12
A61K 31/40

Abstract:

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia,as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

US Patent:

20190225621, Jul 25, 2019

Filed:

Apr 5, 2019

Appl. No.:

16/377005

Inventors:

- BETHESDA MD, US
David Christopher Limburg - Salem CT, US
John Paul Mathias - Concord MA, US
Atli Thorarensen - Stow MA, US
Rajiah Aldrin Denny - Sharon MA, US
Christoph Wolfgang Zapf - Oakland CA, US
Daniel Elbaum - Newman MA, US
Lori Krim Krim Gavrin - Villanova PA, US
Ivan Viktorovich Efremov - Chestnut MA, US

International Classification:

C07D 487/04
A61P 11/12
A61K 31/519
A61K 45/06

Abstract:

The present invention relates to methods of using compounds of Formula I,

US Patent:

20190092750, Mar 28, 2019

Filed:

Nov 30, 2018

Appl. No.:

16/206166

Inventors:

- New York NY, US
CHRISTOPHE PHILIPPE ALLAIS - Ledyard CT, US
CHRISTOPH MARTIN DEHNHARDT - Burnaby, CA
LORI KRIM GAVRIN - Villanova PA, US
SEUNGIL HAN - Mystic CT, US
DAVID HEPWORTH - Concord MA, US
ARTHUR LEE - San Carlos CA, US
FRANK ELDRIDGE LOVERING - Acton MA, US
JOHN PAUL MATHIAS - Concord MA, US
DAFYDD RHYS OWEN - Concord MA, US
NIKOLAOS PAPAIOANNOU - Newton MA, US
EDDINE SAIAH - Brookline MA, US
JOSEPH WALTER STROHBACH - Wentzville MO, US
JOHN DAVID TRZUPEK - Arlington MA, US
STEPHEN WAYNE WRIGHT - Old Lyme CT, US
CHRISTOPH WOLFGANG ZAPF - Marlborough MA, US

Assignee:

PFIZER INC. - New York NY

International Classification:

C07D 401/12
C07D 413/04
A61K 31/4375
A61K 31/4709
A61K 31/4725
A61K 31/4745
A61K 45/06
C07D 401/14
C07D 207/273
C07D 491/18
C07D 471/04
C07D 413/14
A61K 31/4015

Abstract:

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula ,as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

US Patent:

20190016727, Jan 17, 2019

Filed:

Sep 17, 2018

Appl. No.:

16/132894

Inventors:

- Bethesda MD, US
David Christopher Limburg - Salem CT, US
John Paul Mathias - Concord MA, US
Atli Thorarensen - Stow MA, US
John James Mousseau - Norwich CT, US
Rajiah Aldrin Denny - Sharon MA, US
Christoph Wolfgang Zapf - Oakland CA, US
Ivan Viktorovich Efremov - Chestnut MA, US

Assignee:

CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. - Bethesda MD

International Classification:

C07D 487/04
A61P 11/00

Abstract:

The present invention relates to 1,3-disubstituted-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives, 5,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives or 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

Author:

John Mathias

ISBN #:

0689845324